| Species |
Human |
| Protein Construction |
BCMA (Ala5-Ala54)
Accession # Q02223 |
|
| Purity |
> 98% as analyzed by SDS-PAGE
> 98% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40.0 ng/ml, corresponding to a specific activity of > 2.5 × 104 IU/mg in the presence of 100.0 ng/ml human APRIL. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
5.4 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 30% acetonitrile, 0.1% TFA. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
BCMA, a member of the TNF receptor superfamily, binds to BAFF and APRIL. BCMA is expressed on mature B-cells and other B-cell lines and plays an important role in B cell development, function and regulation. BCMA also has the capability to activate NF-kappaB and JNK. The human BCMA gene codes for a 184 amino acid type I transmembrane protein, which contains a 54 amino acid extracellular domain, a 23 amino acid transmembrane domain, and a 107 amino acid extracellular domain. |
| Synonyms |
B-cell maturation protein; CD_antigen: CD269; TNFRSF17; BCM; Tumor necrosis factor receptor superfamily member 17 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
